Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 Biomarker disease BEFREE AE = adverse event CI = confidence interval C<sub>ss,max</sub> = maximum steady-state plasma concentration DCR = disease control rate EGFR = epidermal growth factor receptor ILD = interstitial lung disease MTC = medullary thyroid cancer ORR = objective response rate PFS = progression-free survival PK = pharmacokinetics RECIST = Response Evaluation Criteria in Solid Tumors RET = re-arranged during transfection SAE = serious adverse event VEGFR = vascular endothelial growth factor receptor. 27819766 2017
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 AlteredExpression disease BEFREE Most TNBCs expressing EGFR are non-specialized invasive ductal carcinomas, whereas others are likely to be rare specialized carcinomas, such as typical medullary carcinoma, apocrine carcinoma, metaplastic carcinoma, and adenoid cystic carcinoma. 22481575 2014
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 AlteredExpression disease BEFREE VEGFR1, PDGFRB, VEGF, KIT, and MET were present in 34-20% of the cases, while EGFR was highly expressed in only 10% of the MTC samples. 23780998 2013
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 Biomarker disease BEFREE Vandetanib (ZD6474, Caprelsa, AstraZeneca), an oral small-molecule tyrosine kinase inhibitor (TKI) that targets the rearranged during transfection receptor (RET), VEGF receptor (VEGFR2-3), and EGF receptor (EGFR), is the first systemic therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of symptomatic or progressive advanced medullary thyroid cancer (MTC). 23231950 2013
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 Biomarker disease BEFREE Recently, vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor (VEGFR) 2 and VEGFR 3, RET, and epidermal growth factor receptor (EGFR), was approved for the treatment of adults with symptomatic or progressive MTC. 22343387 2012
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 Biomarker disease BEFREE This open-label, phase II study assessed the efficacy of vandetanib, a selective oral inhibitor of RET, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, in patients with advanced hereditary MTC. 20065189 2010
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 AlteredExpression disease BEFREE EGFR tyrosine kinase domain mutations were not a feature of MTCs; however, EGFR polysomy and a strong EGFR expression were detected in 15 and 13% of the tumors respectively. 19776290 2010
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 AlteredExpression disease BEFREE Several genes relevant to breast cancer metastasis to bone (osteopontin, CTGF, parathyroid hormone receptor, EGFR) were significantly overexpressed in MTCs as compared to DTCs. 19697143 2009
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 Biomarker disease BEFREE Together, our data suggest that RET/EGFR multi-target inhibitors might be beneficial for therapy of MTC. 18756447 2009
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 Biomarker disease BEFREE The prominent co-expression of c-Myc, TGF-alpha and EGFR proteins indicates that in MTC these factors might be of importance for tumour cell proliferation via autocrine growth stimulation. 9247102 1997